Yijun Deng, Ph.D.

Over 20 years of experience in the discovery and development of bioactive molecules with pharmaceutical companies in the USA, including Johnson and Johnson, Viropharma Inc, Tetralogic Pharmaceuticals, and Venatorx Pharmaceuticals.

Key member of the team discovered birinapant, a first-in-class IAP antagonist for cancer treatment at Tetralogic Pharmaceuticals.

Extensive experience in Drug Substance and Drug Product Process Development and Manufacturing under GMP. Played a key role in CMC support to the clinical development of birinapant (TL32711), Remetinostat (SHP-141), and a new b-lactamase inhibitor.

Co-author or co-inventor of more than 30 patents and publications.

Ph.D. in chemistry from Case Western Reserve University, Cleveland, Ohio; MS and BS in chemistry from Sun Yat-sen University.